Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

Sirt2 Inhibition Improves Gut Epithelial Barrier Integrity and Protects Mice from Colitis

April 23, 2024

[Proceedings Of The National Academy Of Sciences Of The United States Of America] Researchers established that small-molecule inhibitors of Sirt2 were promising treatment strategies for inflammatory bowel disease. Small-molecule inhibitors of enzymes had been increasingly used to investigate the biological function of enzymes.

Inhibiting the cGAS-STING Pathway in Ulcerative Colitis with Programmable Micelles

April 23, 2024

[ACS Nano] Programmable nanomicelles were designed for colitis treatment and loaded with RU.521, an inhibitor of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway.

CircSOD2: Disruption of Intestinal Mucosal Barrier Function in Ulcerative Colitis by Regulating the miR-378g/Snail1 Axis

April 23, 2024

[Journal Of Gastroenterology And Hepatology] Lipopolysaccharide-induced Caco2 cells were used to mimic ulceratvie colitis cell models. CircSOD2, miR-378g, and Snail1 levels were determined by quantitative real-time PCR.

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

April 22, 2024

[MEI Pharma, Inc.] MEI Pharma, Inc. reported that 25% of evaluable patients with relapsed metastatic colorectal cancer in Cohort 1 of the ongoing Phase Ib study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation, in combination with bevacizumab had no disease progression at Week 16.

Consistent Signatures in the Human Gut Microbiome of Old- and Young-Onset Colorectal Cancer

April 22, 2024

[Nature Communications] Investigators assembled the largest young-onset colorectal cancer (yCRC) gut metagenomes to date from two independent cohorts and found that the CRC microbiome had limited association with age across adulthood.

Recurrent RhoGAP Gene Fusion CLDN18-ARHGAP26 Promotes RHOA Activation and Focal Adhesion Kinase and YAP-TEAD Signaling in Diffuse Gastric Cancer

April 19, 2024

[Gut] Scientists developed a model to study the function of a fusion protein in the pathogenesis of diffuse gastric cancer (DGC). Using organoids generated from this model, they evaluated its oncogenic activity and the biochemical effects of the fusion protein on the RHOA pathway and its downstream cell biological effects in the pathogenesis of DGC.

DHX9 Maintains Epithelial Homeostasis by Restraining R-Loop-Mediated Genomic Instability in Intestinal Stem Cells

April 19, 2024

[Nature Communications] The authors observed reduced DEAH-box helicase 9 (DHX9) protein levels in IBD patients, and mice with conditional DHX9 depletion in the intestinal epithelium exhibited an increased susceptibility to experimental colitis.

Chymotrypsin Activity Signals to Intestinal Epithelium by Protease-Activated Receptor-Dependent Mechanisms

April 19, 2024

[British Journal Of Pharmacology] Researchers deciphered molecular pharmacological mechanisms and gene expression regulation for chymotrypsin signaling in intestinal epithelial cells.

LPA5-Dependent Signaling Regulates Regeneration of the Intestinal Epithelium Following Irradiation

April 18, 2024

The effects of lysophosphatidic acid (LPA)5 on intestinal stem cells were corroborated by studies using organoids derived from Lgr5-lineage tracking reporter mice with deletion...

Combination of Bazedoxifene with Chemotherapy and SMAC-Mimetics for the Treatment of Colorectal Cancer

April 18, 2024

Researchers provided evidence that bazedoxifene inhibited tumour growth via direct interaction with the gp130 receptor to suppress IL-6 and IL-11-mediated STAT3 signalling. Additionally, bazedoxifene...

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

April 16, 2024

[Palisade Bio, Inc.] Palisade Bio, Inc. announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients affected by ulcerative colitis (UC). PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.

New Research from Case Western Reserve University Aims to Block Tumor Growth in Colorectal Cancer Patients

April 16, 2024

[Case Western Reserve University] With a new five-year, $1.84 million grant from the National Cancer Institute, researchers from Case Western Reserve University hope to take a step closer to developing new treatment options for people with metastatic colorectal cancer by studying how a protein involved in colorectal cancer growth functions.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.